February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

The application is supported by data from a phase 3 trial (ClinicalTrials.gov Identifier: NCT04502693) in which study participants received 2 doses of MenABCWY administered 6 months apart or 2 doses ...

LONDON, Jan. 8, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted ...

Findings showed MenABCWY met the primary endpoint demonstrating noninferiority to 2 doses of Bexsero and 1 dose of Menveo for all 5 Neisseria meningitidis serogroups (A, B, C, W and Y).

The European Commission's approval means Menveo is now licenced for active immunisation of children from 2 years of age, adolescents and adults to help protect against IMD – the leading cause of ...